SaluteTesto originale in inglese
FDA approves weekly Mimrylo injection for rare blood cancer
Protagonist developed the drug, which Takeda will sell under the Mimrylo brand.
Scritto dall’IA2 fonti1 min
Loading…
Diagnosi, protesi, vaccini, genomica: la medicina che guadagna anni di vita.
La medicina che guadagna anni di vita: screening assistiti dall’IA che esaminano milioni di pazienti, vaccini di nuova generazione, una genomica che passa dal sequenziamento alla terapia, protesi e impianti che restituiscono capacità perdute. La rubrica segue le sperimentazioni cliniche concluse, le autorizzazioni all’immissione in commercio, le adozioni ospedaliere — il momento in cui una tecnologia smette di essere una pubblicazione per diventare una cura.
I numeri comandano: coorti, tassi di rilevamento, mortalità evitata, costi. Copriamo volentieri i sistemi sanitari che adottano su larga scala — l’India, il Brasile, il Sud-est asiatico — perché le tecnologie frugali si mettono spesso alla prova lì prima di arrivare altrove. Ogni articolo si appoggia alla sperimentazione, all’autorizzazione o allo studio che lo fonda, e li cita.
Protagonist developed the drug, which Takeda will sell under the Mimrylo brand.
UC Berkeley researchers compared eight Myotis genomes and found a link between longer life spans and cancer-fighting genes.
The 10-year STAREE trial followed nearly 10,000 independently living older adults in Australia.
A trial of 2,501 men found specialist referrals increased statin and blood-pressure treatment.
Danish registers followed 132,585 people diagnosed with type 2 diabetes from 2006 through 2019.
An exploratory analysis found a more favorable long-term quality-of-life trajectory with twice-daily radiation.
The 68 Ga/177 Lu-NYM096 pair uses one compound to image tumors and deliver targeted radiation.
Pacibekitug kept inflammation markers down through day 180 in adults with kidney disease and elevated inflammatory risk associated with heart disease.
TARGET-CTCA randomly assigned 3,170 people across 14 UK emergency departments.
MD Anderson researchers linked BRAF to the development and persistence of pain after nerve injury.
TU Wien researchers implanted cell-loaded DEGRAD INX scaffolds in a rabbit knee defect.
Abbott’s Libre Duo 10 Day reads ketones and glucose every minute for 10 days.
The open-label trial randomized 1,803 people at 18 South Korean centers to DOACs or no anticoagulation.
The University of Virginia team found 69.8% of patients had metastatic disease, including aggressive cancers such as pancreatic cancer.
The randomized trial enrolled 12 adults with drug-resistant epilepsy in Taiwan.
Boston University researchers identified lung-vein cells that become active after injury and promote scar formation.
The study covered 805 adults who received living-donor kidney transplants in Japan between 2001 and 2021.
Screening found HCV in 4.1% of people in custody, versus 0.3% in Hong Kong's general population.